Abstract
Cerebellum is Latin for “little brain” is about a tenth of the brain in size and weight, is in the posterior cranial fossa. It connects directly or indirectly to a variety of structures, including brainstem, spinal cord, cortical and subcortical regions. The cerebellum contains almost 80% of all neurons in the brain and consists of different forms of neuronal units, each sharing basic cerebellar microcircuits. The cerebellum is formed by two lateral hemispheres and vermis or a middle portion .
The cerebellum has several functions: coordinate movements specialized volunteers to influence muscle activity and control the balance, muscle tone through connections with the vestibular system, the spinal cord and alpha motor neurons. Within the cerebellar cortex somatotopic organization exists a body part.
The cerebellum is a key to information processing and participates in numerous motor and non-motor activities, thanks to the anatomical characteristics of its routes, huge analysis capabilities and high connectivity with other brain areas, can be affected by different factors such as abnormalities in embryonic development, toxic, autoimmune, inflammatory, vascular and metabolic, infections, primary and secondary tumors, trauma, iatrogenic, genetic diseases, sporadic, giving rise to signs and symptoms that cause cerebellar syndrome according to compromised anatomical area.
In the scientific literature no reported cases of cerebellar syndrome mesalamina (mesalazina), we report the first case.
References
Roostaei T, Nazeri A, Sahraian MA, Minagar A. The human cerebellum. Neurol Clin. 2014; 32(4):859-69.
Silva Rosas Carlos R. Semiología y fundamentos de la neurología clínica. 1st ed. Chile: Amolca; 75-83.
Waxman SG, Padilla Sierra GE, Olivares Bari SM. Neuroanatomi?a cli?nica [Internet]. 2011 [cited 2015 Apr 18]. Available from: http://site.ebrary.com/id/10751314.
Grimaldi G, Manto M. Topography of cerebellar deficits in humans. Cerebellum. 2012;11(2):336-51.
Schmahmann JD. Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome. J Neuropsychiatry Clin Neurosci. 2004;16(3):367-78.
Bustamante B, Jairo. Neuroanatomi?a funcional y cli?nica: atlas del sistema nervioso central. Volumen. Edición. Bogota?: Me?dica Celsus; 2007.
Purves D. Neurociencia. Volumen. Edición. Buenos Aires: Me?dica Panamericana; 2006.
Uribe Uribe CS. Neurología. Volumen. Edición. Medelli?n.: Corporacio?n para Investigaciones Biolo?gicas; 2010.
Neuroanatomia Clinica / Clinical Neuroanatomy. Volumen. Edición. Lugar de publicación: Lippincott Williams & Wilkins; 2014.
Daroff RB, Bradley WG, editors. Bradley's neurology in clinical practice /: [edited by] Robert B. Daroff ... [et al.]. 6th ed. Philadelphia, PA: Elsevier/Saunders; 2012. 2 p.
Pfiffner TJ, Jani R, Mechtler L. Neuro-oncological Disorders of the Cerebellum. Neurol Clin. 2014;32(4):913-41.
Tornes L, Conway B, Sheremata W. Multiple Sclerosis and the Cerebellum. Neurolo Clin. 2014;32(4):957-77.
Datar S, Rabinstein AA. Cerebellar Infarction. Neurol Clin. 2014 Nov;(4):979-91.
Pruitt AA. Infections of the Cerebellum. Neurol Clin. 2014;32(4):1117-31.
Javalkar V, Khan M, Davis DE. Clinical Manifestations of Cerebellar Disease. Neurol Clin. 2014;32(4):871-9.
Nixon M, Ambekar S, Zhang S, Markham C, Akbarian-Tefaghi H, Morrow K, et al. Traumatic Injury to the Posterior Fossa. Neurol Clin. 2014; 32(4):943-55.
Manto M, Marmolino D. Cerebellar disorders-At the crossroad of molecular pathways and diagnosis. Cerebellum. 2009;8(4):417-22.
Mark RB, Don JM. Drug-induced disorders of the nervous system. Clin Med. 2007;7(2):170-6.
Goodman LS, Brunton LL, Chabner B, Knollmann BC, editors. Goodman & Gilman's pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. 2084 p.
Brand S. Medical therapy of ulcerative colitis. MMW Fortschr Med. 2015, 5;157(2):45-8.
Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD000543.
Rosa N, Giamundo A, Jura A, Iaccarino G, Romano A. Mesalazine-associated benign intracranial hypertension in a patient with ulcerative colitis. Am J Ophthalmol. 2003;136(1):212-3.
Gunnarsson I, Forslid J, Ringertz B. Mesalazine-induced lupus syndrome. Lupus. 1999;8(6):486-8.
Braun M, Fraser GM, Kunin M, Salamon F, Tur-Kaspa R. Mesalamine-induced granulomatous hepatitis. Am J Gastroenterol. 1999 Jul;94(7):1973-4.
Deltenre P, Berson A, Marcellin P, Degott C, Biour M, Pessayre D. Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. Gut. 1999;44(6):886-8.
Morice AH, Kumwenda J, Qureshi N, Curran A. Mesalazine activation of eosinophil. Lancet. 1997, 11;350(9084):1105.
Asirvatham S, Sebastian C, Thadani U. Severe symptomatic sinus bradycardia associated with mesalamine use. Am J Gastroenterol. 1998;93(3):470-1.
Timsit MA, Anglicheau D, Lioté F, Marteau P, Dryll A. Mesalazine-induced lupus. Rev Rhum Engl Ed. 1997;64(10):586-8.
Netzer P. [Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease]. Schweiz Med Wochenschr. 1995;125(50):2438-42.
Nakajima H, Munakata A, Yoshida Y. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. J Gastroenterol. 1995;30 Suppl 8:115-7.
Honeybourne D. Mesalazine toxicity. BMJ. 1994, 19;308(6927):533-4.
Lim AG, Hine KR. Fever, vasculitic rash, arthritis, pericarditis, and pericardial effusion after mesalazine. BMJ. 1994, 8;308(6921):113.
Witte T, Olbricht CJ, Koch KM. Interstitial nephritis associated with 5-aminosalicylic acid. Nephron.1994;67(4):481-2.
Hautekeete ML, Bourgeois N, Potvin P, Duville L, Reynaert H, Devis G, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology. 1992;103(6):1925-7.
Lagler U, Schulthess HK, Kuhn M. Acute alveolitis due to mesalazine. Schweiz Med Wochenschr. 1992, 5;122(36):1332-4.
Erdkamp F, Houben M, Ackerman E, Breed W, van Spreeuwel J. Pancreatitis induced by mesalamine. Neth J Med. 1992;41(1-2):71-3.
Pent MT, Ganapathy S, Holdsworth CD, Channer KC. Mesalazine induced lupus-like syndrome. BMJ. 1992 Jul;305(6846):159.
Masson EA, Rhodes JM. Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. Gut. 1992;33(4):563-4.
Zarranz JJ. , Título del capítulo. En: editor del libro. Neurología. Edición. Barcelona: Elsevier; 2013:674.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.